Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.
Palmeri S, Ponzano M, Ivaldi F, Signori A, Lapucci C, Casella V, Ferrò MT, Vigo T, Inglese M, Mancardi GL, Uccelli A, Laroni A. Palmeri S, et al. Among authors: signori a. CNS Drugs. 2022 Jan;36(1):83-96. doi: 10.1007/s40263-021-00875-0. Epub 2021 Dec 11. CNS Drugs. 2022. PMID: 34894339
Scoring treatment response in patients with relapsing multiple sclerosis.
Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, Stubinski B, Stromillo Ml, Montalban X, De Stefano N. Sormani MP, et al. Among authors: signori a. Mult Scler. 2013 Apr;19(5):605-12. doi: 10.1177/1352458512460605. Epub 2012 Sep 25. Mult Scler. 2013. PMID: 23012253
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis.
Puthenparampil M, Federle L, Poggiali D, Miante S, Signori A, Pilotto E, Rinaldi F, Perini P, Sormani MP, Midena E, Gallo P. Puthenparampil M, et al. Among authors: signori a. PLoS One. 2017 Aug 29;12(8):e0183957. doi: 10.1371/journal.pone.0183957. eCollection 2017. PLoS One. 2017. PMID: 28850630 Free PMC article.
CD8+CD28-CD127loCD39+ regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?
Fenoglio D, Dentone C, Signori A, Di Biagio A, Parodi A, Kalli F, Nasi G, Curto M, Cenderello G, De Leo P, Bartolacci V, Orofino G, Nicolini LA, Taramasso L, Fiorillo E, Orrù V, Traverso P, Bruzzone B, Ivaldi F, Mantia E, Guerra M, Negrini S, Giacomini M, Bhagani S, Filaci G. Fenoglio D, et al. Among authors: signori a. J Allergy Clin Immunol. 2018 Jun;141(6):2220-2233.e4. doi: 10.1016/j.jaci.2017.08.021. Epub 2017 Nov 2. J Allergy Clin Immunol. 2018. PMID: 29103633 Free article.
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP. Saccà F, et al. Among authors: signori a. Mult Scler. 2019 Aug;25(9):1263-1272. doi: 10.1177/1352458518790390. Epub 2018 Jul 25. Mult Scler. 2019. PMID: 30044207 Free article.
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group. Frau J, et al. Among authors: signori a. J Neurol. 2019 Oct;266(10):2440-2446. doi: 10.1007/s00415-019-09424-8. Epub 2019 Jun 17. J Neurol. 2019. PMID: 31209573
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: signori a. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C, Bovis F, Novi G, Capobianco M, Lanzillo R, Frau J, Repice AM, Hakiki B, Realmuto S, Bonavita S, Curti E, Brambilla L, Mataluni G, Cavalla P, Di Sapio A, Signoriello E, Barone S, Maniscalco GT, Maietta I, Maraffi I, Boffa G, Malucchi S, Nozzolillo A, Coghe G, Mechi C, Salemi G, Gallo A, Sacco R, Cellerino M, Malentacchi M, De Angelis M, Lorefice L, Magnani E, Prestipino E, Sperli F, Brescia Morra V, Fenu G, Barilaro A, Abbadessa G, Signori A, Granella F, Amato MP, Uccelli A, Gobbi C, Sormani MP. Zecca C, et al. Among authors: signori a. Mult Scler. 2020 Oct;26(12):1519-1531. doi: 10.1177/1352458519872889. Epub 2019 Oct 1. Mult Scler. 2020. PMID: 31573386
326 results